Drug Profile
Avelumab companion diagnostic - Merck/Pfizer/Dako
Latest Information Update: 28 Oct 2018
Price :
$50
*
At a glance
- Originator Agilent Technologies; Merck KGaA; Pfizer
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Merkel cell carcinoma; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for clinical-Phase-Unknown development in Merkel cell carcinoma(Diagnosis) in USA
- 28 Oct 2018 No recent reports of development identified for clinical-Phase-Unknown development in Non-small-cell-lung-cancer(Diagnosis) in USA
- 28 Oct 2018 No recent reports of development identified for clinical-Phase-Unknown development in Solid-tumours(Diagnosis) in USA